Stories
Acrotech Biopharma Launches ADQUEY in US Dermatology Market for Atopic Dermatitis
C
CNBC TV18•30-09-2026, 22:26
Acrotech Biopharma Launches ADQUEY in US Dermatology Market for Atopic Dermatitis
- •Aurobindo Pharma's arm, Acrotech Biopharma Inc., launched ADQUEY (difamilast 1%) ointment in the US for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and older.
- •ADQUEY is a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, entering a US market estimated at $1.3 billion by July 2026.
- •This launch marks Acrotech's entry into the US dermatology market, supported by a newly established dedicated dermatology business unit.
- •The dermatology unit will focus on building awareness, engaging healthcare professionals, and supporting patients, while also expanding Acrotech's presence in specialty dermatology.
- •Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for US commercialization, aligning with Acrotech's strategy to expand innovative medicines and commercial platforms.
Key Questions Answered
ADQUEY (difamilast 1%) ointment is a non-steroidal topical phosphodiesterase-4 inhibitor launched by Acrotech Biopharma Inc., an arm of Aurobindo Pharma Ltd, for treating mild-to-moderate atopic dermatitis in adults and paediatric patients aged 2 years and older.
Difamilast was originally discovered by Otsuka Pharmaceutical and subsequently licensed to Acrotech Biopharma for commercialisation in the United States.
ADQUEY will compete in a US market estimated at around $1.3 billion for the 12 months ended July 2026, according to IQVIA MAT data.
